Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R mono...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

Iceman89 Aug. 11 at 7:10 PM

$TLSA Excited for the results to see what 100 microgram dosage can do and if it is better than 50.

0 · Reply

Ic0gcds000 Aug. 11 at 5:39 PM

$TLSA Why Buying Stock is Their Only Allowed "Speech"When a CEO cannot legally speak, they use their personal bank account to do the talking.By purchasing nearly 1 million shares of stock on the open market at $1.00 per share just days ago, CEO Ivor Elrifi sent the loudest message legally allowed under SEC rules. It signals to the market that he believes the current $1.00 price is a bargain compared to the private data and corporate interest he is seeing behind closed doors.looking good,.

0 · Reply

JuggernautRaider Aug. 11 at 3:53 PM

$TLSA buying opportunities all kver $CGTX $BMY $PFE 🚀

0 · Reply

Gegau001 Aug. 11 at 5:12 AM

$TLSA We’ll hit a yearly high of $2.70 by the end of September, even without approval... after that, around $3–5... buckle up! 😉

0 · Reply

LDCap Aug. 10 at 9:34 PM

$TLSA There is very low liquidity at this point without ATM. I was thinking it had stopped this morning but still continuing. Tutes will definitely take positions prior to RO. However I think it will have to be at a higher price point now. Breakout is after 1.18 or 1.24 . Holding my breath. It will get very volatile in the leadup to RO. I would expect atleast 1.65 by end of September.

0 · Reply

Laurensian11 Aug. 10 at 8:33 PM

$TLSA - approx 8 million shares traded between 3/8 and 10/8 (when normal daily average circa 300k) - equivalent to approx 11.5% of the last reported available ‘non-large holder’ pool of these - the CEO bought approx 1 million, from his own pocket over the last week or so - but no meaningful change in share price Surely something is afoot 🤔

1 · Reply

Iceman89 Aug. 10 at 5:49 PM

$TLSA Added my last tranche of shares now. I have about two thirds of my portfolio in Tiziana. I'm crazy, but surprisingly calm. The people involved have earned my trust during the last 6 years, so even if the trial results won't be outstanding, then atleast it won't be a scam either like some companies on WS. Good luck everybody!

2 · Reply

LDCap Aug. 10 at 2:31 PM

$TLSA feels like the current raise might be over. We should have enough money in the bank to partnership now. Let's go.

0 · Reply

LDCap Aug. 6 at 11:44 PM

$TLSA price action is suggesting accumulation rather than ATM at play.

1 · Reply

Laurensian11 Aug. 6 at 7:15 PM

$TLSA Another super high volume day, with very little change to the share price. Who’s accumulating? Are things getting exciting?

0 · Reply

Tiziana Life Sciences CEO Ivor Elrifi purchases 321,423 shares

Aug 4, 2026, 7:00 AM EDT - 7 days ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Jul 31, 2026, 7:00 AM EDT - 11 days ago

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

2026-07-22T11:30:23.000Z - 20 days ago

Tiziana Life Sciences chairman Gabriele Cerrone purchases 42,357 shares at 99c

Jul 22, 2026, 7:00 AM EDT - 20 days ago

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

2026-06-25T11:20:37.000Z - 6 weeks ago

Tiziana Life Sciences doses last patient in intranasal foralumab trial

Jun 25, 2026, 7:00 AM EDT - 6 weeks ago

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

2026-06-15T11:42:42.000Z - 2 months ago

Tiziana Life Sciences chairman Gabriele Cerrone purchases 15,000 shares

May 28, 2026, 7:00 AM EDT - 2 months ago

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

2026-05-21T15:05:09.000Z - 2 months ago

Tiziana fully enrolls Phase 2 placebo-controlled MS trial

May 21, 2026, 11:00 AM EDT - 2 months ago

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

2026-05-19T12:13:28.000Z - 3 months ago

Tiziana Life Sciences announces updated intranasal foralumab data

May 19, 2026, 7:00 AM EDT - 3 months ago

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

2026-05-14T13:46:05.000Z - 3 months ago

Tiziana Phase 2 trial for foralumab shows reduced brain inflammation

May 14, 2026, 7:00 AM EDT - 3 months ago

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

2026-04-16T12:01:24.000Z - 4 months ago

Tiziana Life announces publication of preclinical data in bioRxiv preprint

Apr 16, 2026, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Apr 14, 2026, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Apr 1, 2026, 7:00 AM EDT - 4 months ago

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

2026-02-25T12:25:15.000Z - 5 months ago

Tiziana Life Sciences announces new data on nasal foralumab

Feb 25, 2026, 7:00 AM EST - 5 months ago

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

2026-01-20T16:20:10.000Z - 7 months ago

Tiziana Life Sciences announces publication of intranasal foralumab results

Jan 20, 2026, 11:15 AM EST - 7 months ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Jan 16, 2026, 2:45 PM EST - 7 months ago

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

2026-01-16T12:05:16.000Z - 7 months ago

Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering

Jan 16, 2026, 7:00 AM EST - 7 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Jan 9, 2026, 7:00 AM EST - 7 months ago

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

2025-12-29T13:15:44.000Z - 8 months ago

Tiziana Life Sciences files annual safety report for intranasal foralumab

Dec 29, 2025, 8:00 AM EST - 8 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

2025-12-19T16:05:39.000Z - 8 months ago

Tiziana Life Sciences Chairman raises stake to 36% with acquisition of shares

Dec 19, 2025, 11:00 AM EST - 8 months ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Dec 17, 2025, 10:00 AM EST - 8 months ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

2025-12-17T13:50:17.000Z - 8 months ago

Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s trial

Dec 17, 2025, 8:45 AM EST - 8 months ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

2025-12-15T20:15:08.000Z - 8 months ago

Tiziana Life Sciences CEO Ivor Elrifi purchases 163,400 shares

2025-12-15T12:35:32.000Z - 8 months ago

Tiziana Life Sciences announces withdrawal of proposed public offering

Dec 15, 2025, 7:30 AM EST - 8 months ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

2025-12-12T19:15:11.000Z - 8 months ago

Tiziana Life Sciences to dose first patient in Phase 2 Alzheimer’s trial

Dec 12, 2025, 2:10 PM EST - 8 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

2025-12-02T12:05:39.000Z - 9 months ago

Tiziana Life Sciences plans to spinout IL-6 asset into separate listed company

Dec 2, 2025, 7:00 AM EST - 9 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

2025-11-25T13:40:48.000Z - 9 months ago

Tiziana Life announces Phase 2 foralumab study accepted into Healey ALS program

Nov 25, 2025, 8:30 AM EST - 9 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 13, 2025, 8:30 AM EST - 9 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 24, 2025, 8:30 AM EDT - 11 months ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 15, 2025, 8:00 AM EDT - 11 months ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 5, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 1 year ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 10:30 AM EDT - 1 year ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 1 year ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 1 year ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Iceman89 Aug. 11 at 7:10 PM

$TLSA Excited for the results to see what 100 microgram dosage can do and if it is better than 50.

0 · Reply

Ic0gcds000 Aug. 11 at 5:39 PM

0 · Reply

JuggernautRaider Aug. 11 at 3:53 PM

$TLSA buying opportunities all kver $CGTX $BMY $PFE 🚀

0 · Reply

Gegau001 Aug. 11 at 5:12 AM

$TLSA We’ll hit a yearly high of $2.70 by the end of September, even without approval... after that, around $3–5... buckle up! 😉

0 · Reply

LDCap Aug. 10 at 9:34 PM

0 · Reply

Laurensian11 Aug. 10 at 8:33 PM

1 · Reply

Iceman89 Aug. 10 at 5:49 PM

2 · Reply

LDCap Aug. 10 at 2:31 PM

$TLSA feels like the current raise might be over. We should have enough money in the bank to partnership now. Let's go.

0 · Reply

LDCap Aug. 6 at 11:44 PM

$TLSA price action is suggesting accumulation rather than ATM at play.

1 · Reply

Laurensian11 Aug. 6 at 7:15 PM

$TLSA Another super high volume day, with very little change to the share price. Who’s accumulating? Are things getting exciting?

0 · Reply

CEOBuysDisclosures Aug. 6 at 3:35 PM

$TLSA CEO purchased 321,423 shares at $0.99 for a total of $318,909. Elrifi Ivor now owns 4,793,684 shares. https://ceo-buys.com

0 · Reply

LDCap Aug. 6 at 2:25 PM

$TLSA this is coiling up real tight, breakout will be explosive! The floor is set and hardening by the hr.

0 · Reply

upsoon007 Aug. 6 at 11:27 AM

$TLSA https://www.tizianalifesciences.com/tiziana-life-sciences-announces-purchase-of-shares-by-chief-executive-officer-4/ 2nd purchase this week by CEO, in total 1M shares. Now that‘s confidence! Seriously tempted to top up an already overweight position 😅

0 · Reply

Laurensian11 Aug. 5 at 8:44 PM

$TLSA Any idea what the trading volume was for today, yesterday and Monday? My spidey senses are making me consider that the ATM could be in play to cover part / all of the money that could have been realised through the expired $1.25 Warrants. If so, can a new entrant (or entrants) be accumulating pre read out?

1 · Reply

FilingTracker Aug. 5 at 8:31 PM

$TLSA Purchase by CEO: https://filingtracker.ai/filing/1723069/0001213900-26-085710

0 · Reply

LDCap Aug. 5 at 6:01 PM

$TLSA the volume is off the charts again today with price holding well, completely normal behaviour for this little ticker of course.

1 · Reply

LDCap Aug. 5 at 11:10 AM

$TLSA hmmm, not a penny either way.

0 · Reply

BioRich Aug. 5 at 2:30 AM

$SABS, $KYTX, $GUTS, $SGP and $TLSA continue to be my wake up and "Did we get bought?" Bios. Always seems to be the sleepers. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

LDCap Aug. 4 at 4:57 PM

$TLSA you have to be nuts not to buy this. 🤣. These are not token buys by insiders. These are put your money where your mouth is buys. Everyday I get more bullish.

1 · Reply

DataJim Aug. 4 at 4:30 PM

$TLSA the CEO just bought over 600,000 shares. He paid a dollar a share. I just added some more at $.98 so I got a better deal than the CEO.

1 · Reply

jazzv Aug. 4 at 4:04 PM

$TLSA maybe new financing is coming?

0 · Reply

upsoon007 Aug. 4 at 3:53 PM

$TLSA meanwhile share supply for borrowing continues to shrink - by another 500K today after 1M yesterday. Wondering what makes this so attractive for shorting at this price.

0 · Reply

Market Cap	128.53M
Revenue (ttm)	0.00
Net Income (ttm)	-18.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	414,600
Avg Vol	374,748
Day's Range	N/A - N/A
Shares Out	127.26M
Stochastic %K	46%
Beta	0.49
Analysts	Sell
Price Target	$9.00